Project Grant R01CA300059
Award Date
4/4/25
Completion Date
3/31/30
Dollars Obligated
$518K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) will support research to develop novel glycan biomarkers for the early detection and diagnosis of cholangiocarcinoma (CCA), a highly lethal form of liver cancer. The award totals $671,384 and will be provided from December 2024 through November 2029. The primary awardee, the Medical University of South Carolina (MUSC), will lead the effort to identify glycan...
This $1,224,644 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) will support research at the Icahn School of Medicine at Mount Sinai to dissect the role of the immune checkpoint protein B7-H4 in promoting tumor growth and desmoplastic reactions in intrahepatic cholangiocarcinoma (CCA), a deadly form of liver cancer. The research aims to uncover the molecular mechanisms by which B7-H4 interacts with the TGF-beta pathway to shape the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $793,324 to the Beckman Research Institute of the City of Hope to develop selective small molecule inhibitors targeting the CYP8B1 enzyme as a novel approach to treat hepatocellular carcinoma (HCC), including metabolic dysfunction-associated HCC. The key objectives are to: 1) identify CYP8B1 inhibitors through high-throughput screening, 2) validate hit compounds for potency,...
The National Cancer Institute (NCI) awarded a $610,890 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Mayo Clinic to conduct research on a novel combination therapy for intrahepatic cholangiocarcinoma, an aggressive liver cancer. The project aims to evaluate the clinical efficacy of combining external beam radiotherapy, autologous dendritic cell injections, and dual PD-L1/TIGIT checkpoint blockade. The study will assess progression-free survival as the primary endpoint and analyze...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports an investigation into the role of metabolic stress and reprogramming in the progression from non-alcoholic steatohepatitis (NASH) to hepatocellular carcinoma (HCC), the most common form of liver cancer. The $2,397,277 project, awarded on September 9, 2024, with a completion date of August 31, 2029, is being conducted by the Sanford Burnham Prebys Medical Discovery Institute. The project...
This Project Grant award of $1,271,780.00 from the National Cancer Institute under the Cancer Treatment Research federal grant program (CFDA 93.395) supports research at the University of Pittsburgh focused on developing small molecule adaptors for controlling and expanding the capabilities of universal chimeric antigen receptor (CAR) T cell therapies. The key objectives of the research are to: 1) Create small molecule adaptors that can target universal CAR T cells to multiple antigens,...
This Project Grant award, valued at $355,706.00 and funded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research), supports research at the University of Wisconsin - Madison to investigate the mechanisms by which the bile acid receptor FXR regulates the function of gut macrophages and their interactions with other cell types in the development of colitis-associated colorectal cancer (CAC). The overarching goal is to evaluate the therapeutic potential of FXR agonism, including...
The National Cancer Institute (NCI) awarded a $177,000 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Children's Hospital Corporation, doing business as Boston Children's Hospital. The funding supports research to investigate the role of the NLRC4 inflammasome and caspase-8 activation in the pathogenesis of fibrolamellar carcinoma (FLC), a rare and aggressive form of liver cancer. The researchers will use mouse liver organoids engineered with the DNAJB1-PRKACA...
The National Cancer Institute (NCI) awarded a $138,485 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to Loyola University of Chicago's Health Sciences Campus. The grant period runs from September 27, 2024 to March 31, 2028. The purpose of this grant is to define the molecular mechanisms and identify biomarkers for focal adhesion kinase (FAK)-driven hepatocellular carcinoma (HCC). The research aims to: 1) determine the mechanism through which FAK promotes the expression...
The National Cancer Institute (NCI) awarded a $213,284 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Beckman Research Institute of the City of Hope. The purpose of this 17-month grant, with an end date of April 30, 2025, is to determine the role of the CYP8B1 protein in obesity-associated hepatocellular carcinoma (HCC) and to develop novel CYP8B1 inhibitors as potential therapeutic candidates. The grant recipient, Beckman Research Institute, will conduct...